STOCK TITAN

CalciMedica grants Glicklich option on 20,000 shares

The option vests in equal monthly installments beginning August 19, 2026, with full vesting on the date of the 2027 annual meeting.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

CalciMedica, Inc. director Alan Glicklich acquired a director stock option on October 1, 2026, covering the right to buy 20,000 common shares. The option has a $1.64 exercise price and expires September 30, 2036. Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over one year; the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders.

Insider Glicklich Alan
Role Director
Type Security Shares Price Value
Grant/Award Director Stock Option (Right to Buy) F1 20,000 $0.00 $0.00
Holdings After Transaction: Director Stock Option (Right to Buy) — 20,000 contracts (Direct)
Footnotes (1)
  1. F1. Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.
Option underlying shares 20,000 common shares Award dated October 1, 2026
Exercise price $1.64 per share Director stock option
Monthly vesting installment 1/12th of the shares subject to the option Beginning August 19, 2026
Vesting period One year Equal monthly installments
Expiration date September 30, 2036 Director stock option
Director Stock Option (Right to Buy) technical
"Director Stock Option (Right to Buy)"
vest technical
"shares subject to the option vest in equal monthly installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
fully vested technical
"option will in any case be fully vested"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did CALC director Alan Glicklich receive?

Alan Glicklich received an option covering 20,000 common shares on October 1, 2026. It has a $1.64 exercise price and expires September 30, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Glicklich Alan

(Last)(First)(Middle)
C/O CALCIMEDICA, INC.
505 COAST S. BLVD, STE 300-9

(Street)
LA JOLLA CALIFORNIA 92037

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Director Stock Option (Right to Buy)$1.6410/01/2026A20,000 (1)09/30/2036Common Stock20,000$020,000D
Explanation of Responses:
1. Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.
/s/ John Dunn, Attorney-in-Fact10/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading